BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

 
Combined application of rapamycin and atorvastatin improves lipid metabolism in apolipoprotein E-deficient mice with chronic kidney disease
Goo Taeg Oh 1,* (Professor), Eun Ju Song 1,3,# (Research worker), Sanghyun Ahn2,# (Professor), Seung-Kee Min2 (Professor), Jongwon Ha2 (Professor)
1Life Sciences, Ewha Womans University,
2Surgery, Seoul National University College of Medicine,
3Veterinary Physiology, Seoul National University College of Veterinary Medicine
Abstract
Atherosclerosis arising from the pro-inflammatory conditions associated with chronic kidney disease (CKD) increases major cardiovascular morbidity and mortality. Rapamycin (RAPA) is known to inhibit atherosclerosis under CKD and non-CKD conditions, but it can cause dyslipidemia; thus, the co-application of lipid-lowering agents is recommended. Atorvastatin (ATV) has been widely used to reduce serum lipids levels, but its synergic effect with RAPA in CKD remains unclear. Here, we analyzed the effect of their combined treatment on atherosclerosis stimulated by CKD in apolipoprotein E-deficient (ApoE-/-) mice. Oil Red O staining revealed that treatment with RAPA and RAPA+ATV, but not ATV alone, significantly decreased the atherosclerotic lesions in the aorta and aortic sinus, compared to those seen in the control (CKD) group. The co-administration of RAPA and ATV improved the serum lipid profile and enhanced the liver expression levels of genes involved in cholesterol transport (Abcg5), bile acid biosynthesis (Cyp7a1), and lipid metabolism (Pparャ, Apoa1). The CKD group showed increased levels of various genes encoding atherosclerosis-promoting cytokines in the spleen (Tnf-メ, Il-6 and Il-1モ) and aorta (Tnf-メ and Il-4), and these increases were attenuated by RAPA treatment. ATV and RAPA+ATV decreased the levels of Tnf-メ and Il-1モ in the spleen, but not in the aorta. Together, these results indicate that, in CKD-induced ApoE-/- mice, RAPA significantly reduces the development of atherosclerosis by regulating the expression of inflammatory cytokines and the co-application of ATV improves lipid metabolism.
Abstract, Accepted Manuscript(in press) [Submitted on June 23, 2020, Accepted on September 10, 2020]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd